Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Wiese, David A ^a   Thaiwong, Tuddow ^b   Yuzbasiyan Gurkan, Vilma ^b   Kiupel, Matti ^b  

^a MCLAREN REGIONAL MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Basal phenotype; BRCA; Feline; Mammary adenocarcinoma; Triple negative

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; EXPERIMENTAL CAT; FEMALE; GENE LOSS; GENE SEQUENCE; HETEROZYGOSITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CATS; DISEASE MODELS, ANIMAL; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM GRADING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84883277346     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-403     Document Type: Article

References (52)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Morris SR, Carey LA. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007, 8:185-198.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
5. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
6. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011, 24:157-167.
7. Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypically distinct entity. Arch Pathol Lab Med 2010, 134:130-133.
8. Anders CK, Carey LA. Biology, metastatic patterns and treatment of patients withtriple negative breast cancers. Clin Breast Cancer 2009, 9(Suppl 2):S73-S81.
9. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010, 19:312-321.
10. Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, Christiaens MR, Paridaens R, Wildiers H. Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast 2013, Feb 15 [Epub ahead of print].
11. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010, 17:173-176.
12. Hayes H, Milne K, Mandell C. Epidemiological features of feline mammary carcinoma. Vet Rec 1981, 30:476-479.
13. Misdorp W, Else RW, Hellme'n E, Lipscomb TP. Histological classification of mammary tumors of the Dog and Cat. Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, vol. VII. 2nd series. Washington, DC 1999, 1-59.
14. Dias Pereira P, Carvalheira J, Gärtner F. Cell proliferation in feline normal hyperplastic and neoplastic mammary tissue--an immunohistochemical study. Vet J 2004, 168:180-185.
15. Hahn K, Bravo L, Avenell J. Feline breast carcinoma as a pathologic andtherapeutic model for human breast cancer. In Vivo 1994, 8:825-828.
16. Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M. Feline mammary tumours in comparative oncology. J Dairy Res 2005, 72(Spec No):98-106.
17. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, Uzzau S, Antuofermo E. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156.
18. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V. An Immunohistochemical study of HER2 expression in feline mammary tumours. J Comp Pathol 2011, 144:170-179.
19. Hamilton JM, Else RW, Forshaw P. Oestrogen receptors in feline mammary carcinoma. Vet Rec 1976, 99:477-479.
20. Rutteman GR, Blankenstein MA, Minke J, Misdorp W. Steroid receptors in mammary tumours of the cat. Acta Endocrinol (Copenh) 1991, 125(Suppl 1):32-37.
21. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci 2005, 79:225-232.
22. Mulas JM DL, van Niel M, Millán Y, Blankenstein MA, van Mil F, Misdorp W. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol 2000, 18:111-125.
23. Mulas JM DL, Van Niel M, Millán Y, Ordás J, Blankenstein MA, Van Mil F, Misdorp W. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci 2002, 72:153-161.
24. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005, 65:907-912.
25. Ordas J, Millan Y, Dios R, Reymundo C, De las Mulas JM. Proto-oncogene HER2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179-184.
26. Hughes K, Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J 2012, 194:19-26.
27. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Sciencen 1994, 266:66-71.
28. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
29. Miller BJ, Wang D, Krahe R, Wright FA. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 2003, 73:748-767.
30. Osorio A, de la Hoya M, Rodríguez-López R, Martínez-Ramírez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldés T, Benítez J. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002, 99:305-309.
31. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
32. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318.
33. Veer LJ VT, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histologic grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991, 19:403-410.
35. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002, 39:529-535.
36. Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 2007, 16:280-292.
37. Oetting WS, Lee HK, Flanders DJ, Wiesner GL, Sellers TA, King RA. Linkage analysis with multiplexed short tandem repeat polymorphisms using infrared fluorescence and M13 tailed primers. Genomics 1995, 30:450-458.
38. Powell CA, Klares S, O'Connor G, Brody JS. Loss of heterozygosity in epithelial cells obtained by bronchial brushings: clinical utility in lung cancer. Clin Cancer Res 1999, 5:2025-2034.
39. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol 1998, 119:263-275.
40. Morgan MP, Cooke MM, McCarthy GM. Microcalcifications associated with breast cancer: an epiphenoenon or biologically significant feature of selected tumors?. J Mammary Gland Biol Neoplasia 2005, 10:181-187.
41. Tornos C, Silva E, el Naggar A, Pritzker KP. Calcium oxalate crystals in breast biopsies. The missing microcalcifications. Am J Surg Pathol 1990, 14:961-968.
42. Zafrani B, Aubriot MH, Mouret E, De Crémoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelénat H, Sastre-Garau X. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000, 37:536-545.
43. Lal P, Tan LK, Chen B. Correlation of HER2 status with estrogen and Progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005, 123:541-546.
44. Winston J, Craft DM, Scase TJ, Bergman PJ. Immunohistochemical detection of HER2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 2005, 3:8-15.
45. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005, 42:30-34.
46. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian Breast & Colorectal Cancer Study Group Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER2 protein expression in breast cancer. Clin Cancer Res 2001, 7:1669-1675. Austrian Breast & Colorectal Cancer Study Group.
47. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009, 22:1457-1467.
48. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J ClinOncol 2010, 28:2784-2795.
49. Ibarra JA, Rogers LW, Kyshtoobayeva A, Bloom K. Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol 2010, 133:747-755.
50. Arber DA. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunhohistochem Mol Morphol 2002, 10:183-186.
51. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-2310.
52. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007, 14:419-430.